BMS-345541 targets inhibitor of κB kinase and induces apoptosis in melanoma: Involvement of nuclear factor κB and mitochondria pathways

Clinical Cancer Research

Volumn 12, Issue 3 I, 2006, Pages 950-960

  Yang, Jinming ^a   Amiri, Katayoun I ^a,b   Burke, James R ^c   Schmid, Johannes A ^d   Richmond, Ann ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 345541; BORTEZOMIB; CHEMOKINE; ENZYME INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL X; SMALL INTERFERING RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER MODEL; CELL DEATH; CELL SURVIVAL; CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MICROSCOPY; MITOCHONDRION; NICK END LABELING; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TOXICITY;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; I-KAPPA B KINASE; IMIDAZOLES; MELANOMA; MICE; MITOCHONDRIA; NF-KAPPA B; QUINOXALINES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 32944468414     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1220     Document Type: Article

References (47)

1. Wolchok JD, Livingston PO. Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol 2001;2:205-11.
2. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
3. Wang CY, Guttridge DC, Mayo MW, Baldwin AS, Jr. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999;19:5923-9.
4. Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 1997;278:860-6.
5. Huxford T, Huang DB, Malek S, Ghosh G. The crystal structure of the IκBα/NF-κB complex reveals mechanisms of NF-κB inactivation. Cell 1998;95:759-70.
6. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionary conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
7. Richmond A. NF-κB, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002;2:664-74
8. Orlowski RZ, Baldwin AS, Jr. NF-κB as a therapeutic target in cancer. Trends Mol Med 2002;8:385-9.
9. Yang J, Richmond A. Constitutive IκB kinase activity correlates with nuclear factor-κB activation in human melanoma cells. Cancer Res 2001;61:4901-9.
10. Haghnegahdar H, Du J, Wang D, et al. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J Leukoc Biol 2000;67:53-62.
11. Yang J, Luan J, Yu Y, et al. Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame. Cancer Res 2001;61:8150-7.
12. Burke JR, Pattoli MA, Gregor KR, et al. BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J Biol Chem 2003;278:1450-6.
13. Yang J, Fan GH, Wadzinski BE, Sakurai H, Richmond A. Protein phosphatase 2A interacts with and directly dephosphorylates RelA. J Biol Chem 2001;276:47828-33.
14. Telford WG, King LE, Fraker PJ. Rapid quantitation of apoptosis in pure and heterogeneous cell populations using flow cytometry. J Immunol Methods 1994;172:1-16.
15. Liptay S, Weber CK, Ludwig L, et al. Mitogenic and antiapoptotic role of constitutive NF-κB/Rel activity in pancreatic cancer. Int J Cancer 2003;105:735-46.
16. Frick S, Lischner S, Rosien F, et al. Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis. Hautarzt 2002;53:659-65.
17. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996;274:787-9.
18. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV. IκB kinase-β: NF-κB activation and complex formation with IκB kinase-α and NIK. Science 1997;278:866-9.
19. Sylla BS, Temin HM. Activation of oncogenicity of the c-rel proto-oncogene. Mol Cell Biol 1986;6:4709-16.
20. White DW, Pitoc GA, Gilmore TD. Interaction of the v-Rel oncoprotein with NF-κB and IκB proteins: heterodimers of a transformation-defective v-Rel mutant and NF-2 are functional in vitro and in vivo. Mol Cell Biol 1996;16:1169-78.
21. Welch DR, Bisi JE, Miller BE, et al. Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int J Cancer 1991;47:227-37.
22. Schmid JA, Birbach A, Hofer-Warbinek R, et al. Dynamics of NF-κB and IκBα studied with green fluorescent protein (GFP) fusion proteins. Investigation of GFP-p65 binding to DNA by fluorescence resonance energy transfer. J Biol Chem 2000;275:17035-42.
23. Zamzami N, Marchetti P, Castedo M, et al. Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett 1996;384:53-7.
24. Henry-Mowatt J, Dive C, Martinou JC, James D. Role of mitochondrial membrane permeabilization in apoptosis and cancer. Oncogene 2004;23:2850-60.
25. Boya P, Morales MC, Gonzalez-Polo RA, et al. The chemopreventive agent N-(4-hydroxyphenyl) retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family. Oncogene 2003;22:6220-30.
26. Zhang XD, Gillespie SK, Mersey P. Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways. Mol Cancer Ther 2004;3:187-97.
27. Arnoult D, Parone P, Martinou JC, et al. Mitochondrial release of apoptosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli. J Cell Biol 2002;159:923-9.
28. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-51.
29. Richmond A, Lawson DH, Nixon DW, Chawla RK. Characterization of autostimulatory and transforming growth factors from human melanoma cells. Cancer Res 1985;45:6390-4.
30. Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-κB in p53-mediated programmed cell death. Nature 2000;404:892-7.
31. Liu Y, Tergaonkar V, Krishna S, Androphy EJ. Human papillomavirus type 16 E6-enhanced susceptibility of L929 cells to tumor necrosis factor-α correlates with increased accumulation of reactive oxygen species. J Biol Chem 1999;274:24819-27.
32. Cahir-McFarland E, Kieff E. NF-κB inhibition in EBV-transformed lymphoblastoid cell lines. Recent Results Cancer Res 2002;159:44-8.
33. Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000;96:2537-42.
34. Fujioka S, Sclabas GM, Schmidt C, et al. Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis. Oncogene 2003;22:1365-70.
35. Raisova M, Hossini AM, Eberle J, et al. The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 2001;117:333-40.
36. Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G. Linking JNK signaling to NF-κB: a key to survival. J Cell Sci 2004;117:5197-208.
37. Saile B, Matthes N, El Armouche H, Neubauer K, Ramadori G. The bcl, NF-κB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-β or TNF-α on activated hepatic stellate cells. Eur J Cell Biol 2001;80:554-61.
38. Ricca A, Biroccio A, Del Bufalo D, et al. bcl-2 overexpression enhances NF-κB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells. Int J Cancer 2000;86:188-96.
39. Paris R, Morales A, Coll O, et al. Ganglioside GD3 sensitizes human hepatoma cells to cancer therapy. J Biol Chem 2002;277:49870-6.
40. Thomenius MJ, Wang NS, Reineks EZ, Wang Z, Distelhorst CW. Bcl-2 on the endoplasmic reticulum regulates Bax activity by binding to BH3-only proteins. J Biol Chem 2003;278:6243-50.
41. Bae J, Hsu SY, Leo CP, Zell K, Hsueh AJ. Underphosphorylated BAD interacts with diverse antiapoptotic Bcl-2 family proteins to regulate apoptosis. Apoptosis 2001;6:319-30.
42. Klein JA, Longo-Guess CM, Rossmann MP, et al. The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature 2002;419:367-74.
43. Ye H, Cande C, Stephanou NC, et al. DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat Struct Biol 2002;9:680-4.
44. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-6.
45. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001;412:95-9.
46. Yuste VJ, Moubarak RS, Delettre C, et al. Cysteine protease inhibition prevents mitochondrial apoptosis-inducing factor (AIF) release. Cell Death Differ 2005;12:1445-8.
47. Suzuki Y, Imai Y, Nakayama H, et al. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 2001;8:613-21.